Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
作者信息
Harbeck Nadia, Ciruelos Eva, Jerusalem Guy, Müller Volkmar, Niikura Naoki, Viale Giuseppe, Bartsch Rupert, Kurzeder Christian, Higgins Michaela J, Connolly Roisin M, Baron-Hay Sally, Gión María, Guarneri Valentina, Bianchini Giampaolo, Wildiers Hans, Escrivá-de-Romaní Santiago, Prahladan Manoj, Bridge Helen, Kuptsova-Clarkson Nataliya, Scotto Nana, Verma Sunil, Lin Nancy U
机构信息
Breast Center, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany.
Hospital Universitario 12 de Octubre, Madrid, Spain.
出版信息
Nat Med. 2024 Dec;30(12):3780. doi: 10.1038/s41591-024-03349-0.
Abstract
摘要
相似文献
1
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.出版商更正：曲妥珠单抗德鲁昔单抗用于伴或不伴脑转移的HER2阳性晚期乳腺癌：一项3b/4期试验。
Nat Med. 2024 Dec;30(12):3780. doi: 10.1038/s41591-024-03349-0.
2
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.曲妥珠单抗-德鲁替康（DS-8201a）治疗既往接受过曲妥珠单抗-美坦新偶联物治疗的晚期 HER2 阳性乳腺癌患者：一项剂量扩展、I 期研究。
Lancet Oncol. 2019 Jun;20(6):816-826. doi: 10.1016/S1470-2045(19)30097-X. Epub 2019 Apr 29.
3
Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report.使用安罗替尼和曲妥珠单抗德鲁昔单抗治疗HER2阳性乳腺癌脑转移：一例报告
Int J Womens Health. 2024 Jul 29;16:1277-1283. doi: 10.2147/IJWH.S472628. eCollection 2024.
4
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.曲妥珠单抗-deruxtecan（DS-8201a）治疗晚期 HER2 阳性胃癌患者：一项剂量扩展、1 期研究。
Lancet Oncol. 2019 Jun;20(6):827-836. doi: 10.1016/S1470-2045(19)30088-9. Epub 2019 Apr 29.
5
TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases.TUXEDO-4：曲妥珠单抗-德曲妥珠单抗治疗伴有新发性或进展性脑转移的HER2低表达乳腺癌的II期研究。
Future Oncol. 2025 Apr;21(9):1065-1073. doi: 10.1080/14796694.2025.2470604. Epub 2025 Feb 28.
6
Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.曲妥珠单抗-德鲁替康：在不可切除或转移性 HER2 阳性乳腺癌中的应用评价。
Target Oncol. 2023 May;18(3):463-470. doi: 10.1007/s11523-023-00971-9. Epub 2023 May 2.
7
Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma.曲妥珠单抗-德鲁替康：在胃癌或胃食管结合部腺癌中的应用评价。
Target Oncol. 2023 Nov;18(6):981-989. doi: 10.1007/s11523-023-00998-y. Epub 2023 Oct 3.
8
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.曲妥珠单抗-德鲁替康治疗 HER2 阳性乳腺癌伴脑转移：一项单臂、2 期临床试验。
Nat Med. 2022 Sep;28(9):1840-1847. doi: 10.1038/s41591-022-01935-8. Epub 2022 Aug 8.
9
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.恩美曲妥珠单抗治疗既往 HER2 阳性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.
10
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.曲妥珠单抗-德曲妥珠单抗用于既往治疗的 HER2 低表达晚期乳腺癌。
N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5.
引用本文的文献
1
Drug treatment of breast cancer brain metastases: progress and challenges.乳腺癌脑转移的药物治疗：进展与挑战
Discov Oncol. 2025 Jun 7;16(1):1025. doi: 10.1007/s12672-025-02820-9.
2
Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial.帕妥珠单抗德卢替康用于实体瘤软脑膜转移疾病：2期TUXEDO-3试验
Nat Med. 2025 May 30. doi: 10.1038/s41591-025-03744-1.
3
Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy.曲妥珠单抗德鲁昔单抗在基于吡咯替尼的治疗失败后的HER2阳性脑转移乳腺癌患者中的疗效和安全性。
Sci Rep. 2025 May 22;15(1):17731. doi: 10.1038/s41598-025-02550-6.
4
Excellent Response to Trastuzumab Deruxtecan of a Large Medullary Metastasis from Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Case Report.曲妥珠单抗德鲁替康对人表皮生长因子受体2阳性乳腺癌大髓样转移灶的卓越疗效：一例报告
Case Rep Oncol. 2025 Mar 29;18(1):523-530. doi: 10.1159/000545577. eCollection 2025 Jan-Dec.
5
Trastuzumab deruxtecan in HER2 overexpressing non-small cell lung cancer (NSCLC).曲妥珠单抗德曲妥珠单抗用于HER2过表达的非小细胞肺癌（NSCLC）。
Transl Lung Cancer Res. 2025 Feb 28;14(2):314-322. doi: 10.21037/tlcr-24-968. Epub 2025 Feb 24.
6
Management of nausea and vomiting induced by antibody-drug conjugates.抗体药物偶联物所致恶心和呕吐的管理
Breast Cancer. 2025 Mar;32(2):278-285. doi: 10.1007/s12282-025-01670-1. Epub 2025 Jan 29.
7
Cerebral spinal fluid analyses and therapeutic implications for leptomeningeal metastatic disease.脑脊液分析及软脑膜转移瘤的治疗意义
J Neurooncol. 2025 Mar;172(1):31-40. doi: 10.1007/s11060-024-04902-0. Epub 2024 Dec 20.
Zotero 插件